Norovirus vaccine developer HilleVax stock climbs 10% following upsized $200M IPO
By Val kennedy, Norovirus vaccine developer HilleVax (HLVX) shares rose 10% following its upsized $200M initial public offering. Shares of HLVX opened at $18.76 after pricing at $17 per share. The stock recently changed hands at $18.70, up 10%, at approximately 12:00 p.m. ET. HLVX offered approximately 11.8M shares priced at $17 per share, raising[…]